and large primary tumours and fewer suspected and proved recurrences and deaths from metastases on levamisole in patients with extended tumours. Distant recurrences tended to be less common with levamisole, whereas the disease-free interval in relapsing patients was almost identical in the two groups.
models levamisole does not influence the growth of the primary tumour but prolongs the remission period after chemotherapy. '6 7 In patients with cancer levamisole restores skin reactivity to 2,4-dinitrochlorobenzene (DNCB) and purified protein derivative (P.P.D.) '8-20 Double-blind treatment and follow-up examinations will be continued in these patients until they develop clinical evidence of recurrence or for at least two years after surgery. The interim analysis reported here was performed after 111 patients had been followed-up for at least one year. The whole study will be completed when 200 patients have been followed for two years.
At selection (at least 15 days before the operation) data on the patient, his tumour location, and his smoking habits were recorded, and a sensitization test with 2 mg DNCB was performed. Five days before surgery a test with 25, 50, and 100 lAg DNCB and an intradermal reaction with 10 IU of P.P.D. were performed, followed by an assessment 48 hours later-that is, just before the start of treatment. These skin tests were repeated 10 days and two months after surgery. After surgical removal the tumours were fixed with formalin 10% Bouin fixative and their greatest and smallest diameters were measured.
To establish the regional extent of the tumour a slightly modified category grouping system, previously described by Slack,2' was adopted: category 1 were also fewer deaths from carcinoma among the levamisole-treated group (15-0% v. 33%), though the difference was not significant. The above data were also confirmed by the findings concerning the total extent gradings. There was no difference between levamisole and placebo among grade I patients, but among grade II patients 20 0% of those on levamisole had suspected recurrences compared with 73-9% of those on placebo (P=0-002). On levamisole 6-7% died from cancer compared with 43-5% on placebo (P=0-026).
Since we expected that several of the indices which were relevant in assessing the effectiveness of levamisole could be interrelated we analysed their relationships (table III) . As expected, the size and the regional extent category were interrelated, but patients who smoked more than 10 cigarettes daily had larger and more extensive tumours than the other patients. On the other hand, patients with squamous cell carcinoma tended to have a tumour extent similar to that of the other patients.
The incidence of intrathoracic recurrences was similar in the two groups (six (11-8%) in levamisole group, seven (11-7%) in placebo group), but distant recurrences (in bone, brain, and liver) tended to be less common on levamisole than on placebo (four (7-8%) and 13 (21-7%) respectively; P=0-06).
The disease-free interval-that is, the time between surgery and evidence of recurrence-in patients who relapsed is shown in fig. 2 it is not surprising that it should be affected beneficially by immunopotentiation. The explanation of the importance of the extent of the tumour (which also seemed to be responsible for the good results on levamisole in heavy smokers) might be found in animal experiments, which have shown that tumour-specific immunity is depressed in animals with large tumours, that this depression is greater when the tumour is larger, and that immunity is restored after cytoreductive therapy-that is, surgery or radiotherapy-but after a certain latent period." The latent period for the reappearance of specific cell-mediated immunity is also related to the type of experimental tumour model.34 Hence, levamisole seems to exert its beneficial effect, at least in part, by preventing immunosuppression due to surgery, especially in patients with large tumours and, therefore, with pre-existing suppression of tumour-specific immunity.
For future research with levamisole patients should be classified according to the extent of their tumour, levamisole should be started before surgery, and the site of recurrence should be registered carefully.
Ringers' lactate solution,6 and that a typical intravenous infusion set adsorbs another 50% of the remaining insulin.
Reports have shown that addition of human serum albumin (H.S.A.) to dilute solutions containing insulin greatly reduces insulin adsorption. 5 We have used gelatin solutions to mimic the action of serum in insulin radioimmunoassay,8 and in later assays substitution of a commercial 3-5% polygeline solution (polymer of degraded gelatin; Haemaccel, HoechstBehringwerke) proved equally effective. It seemed likely that this medium, which is normally used as a plasma substitute, would also be suitable as an insulin carrier solution.s
We describe here studies of the effectiveness of polygeline as a carrier solution for low-level insulin infusion for periods of up to eight hours.
Methods
We added 20 units of crystalline porcine insulin (Novo Actrapid, concentration 40 kU/1) to the following standard 500-ml containers: (a) a plastic container holding polygeline 3-5%; (b) a glass container holding polygeline 3 5%; (c) a glass container holding saline 0-9% and H.S.A. 2% (Commonwealth Serum Laboratories, Melbourne); (d) a glass container holding saline 0-9%; and (e) a plastic container holding saline 0-9%.
The solutions were mixed by agitating the containers, and 15 minutes after the addition of insulin aliquots were taken for assay. The containers were then connected to controlled paediatric drip sets and each adjusted to a flow rate of about 1 ml/min. The effluent was collected-for insulin assay after two and a half, five, and eight hours. The experiment was performed at 22'C. Immediately after collection samples were frozen in plastic tubes and stored at -20°C. Later they were thawed, diluted to 1/700, and assayed for immunoreactive insulin using a commercial radioimmunoassay kit (Sorin, Italy). The quoted oontent of the original insulin phial was also checked by radioimmunoassay. In pilot studies insulin standard curves set up in buffer and in the above carrier solutions diluted to 1/700 were equivalent.
In a further experiment to investigate the relation of insulin recovery to concentration of polygeline in the carrier solution 500-ml glass infusion containers were set up with saline as a diluent to produce a range of concentrations of polygeline from 0 to 3-5%. After addition of insulin as in the first experiment the solutions were left standing at 22°C
